Figure 2.
Figure 2. Overall and disease-free survival. (A) Overall and disease-free survival of all patients entered into the study. The solid line represents overall survival at 5 years, 79.5% (CI, 69.3%-89.7%). The dotted line represents disease-free survival at 5 years, 48.9% (CI, 37.8%-60.7%). (B) Overall and disease-free survival from the point of transplantation. The solid line represents overall survival of 77.5% at 5 years (CI, 57.2%-97.8%). The dotted line represents disease-free survival of 51.5% at 5 years (CI, 33.2%-69.8%). (C) Overall survival from trial entry of patients receiving an autograft and of patients not undergoing transplantation. The solid line represents overall 5-year survival (88.6%) of patients who had autografts (CI, 77.8%-99.4%). The dotted line represents overall survival of patients who did not receive an autograft, 78.6% at 5 years (CI, 51.3%-100.0%). (D) Disease-free survival measured from trial entry of patients receiving an autograft and of patients not undergoing autografting. The solid line represents disease-free survival of patients who received an autograft, 64.7% at 5 years (CI, 50.4%-79.0%). The dotted line represents disease-free survival of patients who did not receive an autograft, 28.8% at 5 years (CI, 4.2%-53.4%).

Overall and disease-free survival. (A) Overall and disease-free survival of all patients entered into the study. The solid line represents overall survival at 5 years, 79.5% (CI, 69.3%-89.7%). The dotted line represents disease-free survival at 5 years, 48.9% (CI, 37.8%-60.7%). (B) Overall and disease-free survival from the point of transplantation. The solid line represents overall survival of 77.5% at 5 years (CI, 57.2%-97.8%). The dotted line represents disease-free survival of 51.5% at 5 years (CI, 33.2%-69.8%). (C) Overall survival from trial entry of patients receiving an autograft and of patients not undergoing transplantation. The solid line represents overall 5-year survival (88.6%) of patients who had autografts (CI, 77.8%-99.4%). The dotted line represents overall survival of patients who did not receive an autograft, 78.6% at 5 years (CI, 51.3%-100.0%). (D) Disease-free survival measured from trial entry of patients receiving an autograft and of patients not undergoing autografting. The solid line represents disease-free survival of patients who received an autograft, 64.7% at 5 years (CI, 50.4%-79.0%). The dotted line represents disease-free survival of patients who did not receive an autograft, 28.8% at 5 years (CI, 4.2%-53.4%).

Close Modal

or Create an Account

Close Modal
Close Modal